Drug Profile

MABS 01

Alternative Names: MABS-01

Latest Information Update: 23 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Manhattan BioSolutions
Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

23 Jan 2025 Preclinical trials in Cancer in USA (Parenteral), before January 2025 (Manhattan BioSolutions pipeline, January 2025)
24 May 2023 Early research in Cancer in USA (Parenteral) before May 2023 (Manhattan BioSolutions website, May 2023)
20 Jul 2022 Manhattan BioSolutions and National Institutes of Health enter into licensing agreements for monoclonal antibodies

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com